RxMD and GlycoRegImmune enter drug development collaboration

RxMD, Inc., a privately-held, global therapeutics development company, today announced a collaboration agreement with GlycoRegImmune Inc. (GRI) to develop new treatments for inflammatory, autoimmune, and neurodegenerative conditions based on GRI's novel natural killer (NK) T cell targeted technologies.

“RxMD's approach is perfect for an early stage company like ours seeking to preserve resources for ongoing discovery”

Under the agreement, RxMD will use its global drug development expertise, including its team of physician-scientists in Chennai, India, to advance GRI's portfolio of drug candidates. The collaboration represents a new model for risk-sharing, success-based drug development.

"RxMD's approach is perfect for an early stage company like ours seeking to preserve resources for ongoing discovery," said Marc Hertz, Ph.D., CEO of GRI. "We now have full access to RxMD's world-class drug development capabilities, which will allow us to design and execute development strategies for our drug candidates much more rapidly and efficiently."

"We are very excited to partner with the outstanding discovery team at GRI to help jump start clinical development of their promising portfolio," said Sanjay Shukla, M.D., CEO of RxMD. "There is tremendous potential for GRI's NK T cell research platforms to improve the lives of patients in many therapeutic areas and we look forward to collaborating with GRI to build a pipeline of new medicines for serious un- or under-treated conditions."